Japanese drugmaker Kyorin Pharmaceutical and R-Pharm, one of Russia’s largest pharmaceutical producers, have reached a basic agreement for activities in Russia and neighboring nations related to the development and marketing of Kyorin’s imidafenacin, a treatment for overactive bladder (OAB).
Under the terms of the agreement, Kyorin grants R-Pharm exclusive rights to activities related to the development and marketing of imidafenacin in Russia and neighboring nations. Imidafenacin is a novel anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze